Financial Analysis: Carmell (CTCX) versus The Competition

Earnings & Valuation

This table compares Carmell and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Carmell	$32,839.00	-$15.44 million	-1.17
Carmell Competitors	$170.32 million	-$17.87 million	-10.54

Carmell’s peers have higher revenue, but lower earnings than Carmell. Carmell is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

24.2% of Carmell shares are held by institutional investors. Comparatively, 40.1% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 29.0% of Carmell shares are held by company insiders. Comparatively, 14.0% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Carmell has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Carmell’s peers have a beta of 3.81, meaning that their average share price is 281% more volatile than the S&P 500.

Profitability

This table compares Carmell and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Carmell	N/A	-217.50%	-50.22%
Carmell Competitors	-1,253.12%	-231.08%	-33.37%

Summary

Carmell beats its peers on 5 of the 9 factors compared.

About Carmell

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.